Pregabalin Capsule
Product Images NDC 76282-574

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 76282-574). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (100 mg)

Pregabalin Capsules 100 mg oral capsules in a 90-count package labeled by Exelan Pharmaceuticals Inc. The label includes usage instructions, storage conditions, child-resistant packaging information, and manufacturing details by InvaGen Pharmaceuticals, Inc. and Exelan Pharmaceuticals, Inc. It also displays the NDC 76282-571-90 and a barcode.*

FDA Label Image

Principal Display Panel (150 mg)

Label for Pregabalin Capsules 150 mg by Exelan Pharmaceuticals Inc. The label indicates 90 capsules in the package and states the product is Rx Only. It includes dosing notes, storage instructions, child-resistance information, and manufacturer details, including InvaGen Pharmaceuticals and Exelan Pharmaceuticals locations.*

FDA Label Image

Principal Display Panel (200 mg)

Label for Pregabalin Capsules 200 mg by Exelan Pharmaceuticals Inc. The label includes the NDC 76282-573-90 and specifies that the package contains 90 capsules. The label states each capsule contains 200 mg of pregabalin, and includes storage instructions, child-resistant packaging notice, and manufacturer information for InvaGen Pharmaceuticals, Inc. and Exelan Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (225 mg)

Label for Pregabalin Capsules 225 mg by Exelan Pharmaceuticals Inc. The label shows the active ingredient Pregabalin and the strength 225 mg in oral capsule form. The package contains 90 capsules. It includes instructions for pharmacists to dispense the Medication Guide and notes the package is child-resistant. Manufacturer information is shown as InvaGen Pharmaceuticals, Inc. and Exelan Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (25 mg)

Pregabalin 25 mg Capsules label by Exelan Pharmaceuticals Inc. The label shows a bottle containing 90 oral capsules of pregabalin. It includes dosage strength (25 mg), manufacturer details, child-resistant packaging notice, storage instructions, and a barcode with NDC 76282-568-90.*

FDA Label Image

Principal Display Panel (300 mg)

Pregabalin Capsules 300 mg oral capsules label by Exelan Pharmaceuticals Inc. The label includes the NDC number 76282-575-90, states the package contains 90 capsules, and the dosage strength of 300 mg. It notes pharmacist dispensing instructions, storage conditions at 20° to 25°C, child-resistant packaging, and manufacturer information for InvaGen Pharmaceuticals and Exelan Pharmaceuticals.*

FDA Label Image

Principal Display Panel (50 mg)

Label for Pregabalin Capsules 50 mg, oral dosage form, by Exelan Pharmaceuticals Inc. The package contains 90 capsules and includes NDC 76282-569-90. Instructions mention the package is child-resistant and storage conditions are 20° to 25°C (68° to 77°F). Manufacturer details for Invagen Pharmaceuticals, Inc. and Exelan Pharmaceuticals are provided.*

FDA Label Image

Principal Display Panel (75 mg)

Pregabalin Capsules 75 mg oral capsules package label by Exelan Pharmaceuticals Inc. The label states the package contains 90 capsules and includes storage instructions and safety warnings. Manufactured by InvaGen Pharmaceuticals and distributed by Exelan Pharmaceuticals.*

FDA Label Image

Figure 1 (Pregabalincaps Fig01)

A line graph showing percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares results for Pregabalin at 25 mg, 100 mg, and 200 mg taken three times a day, and a placebo group, illustrating trends in patient pain improvement rates across dose levels.*

FDA Label Image

Figure 2 (Pregabalincaps Fig02)

A comparative line graph depicting percent of patients improved versus percent improvement in pain from baseline. It contrasts Pregabalin 100 mg three times a day with placebo, illustrating higher patient improvement rates for Pregabalin across increasing pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalincaps Fig03)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin capsules at doses of 75 mg, 150 mg, and 300 mg taken two times a day, as well as placebo. The x-axis shows percent improvement in pain from baseline, ranging from 0 to 100, and the y-axis shows the percent of patients improved, ranging from 0 to 100. The graph includes vertical reference lines at specific improvement percentages.*

FDA Label Image

Figure 4 (Pregabalincaps Fig04)

A line graph showing the relationship between percent improvement in pain from baseline (x-axis) and percent of patients improved (y-axis) for Pregabalin at 200 mg and 100 mg three times a day, compared to placebo. The graph illustrates a higher percentage of patients improved with Pregabalin doses versus placebo across varying levels of pain improvement.*

FDA Label Image

Figure 5 (Pregabalincaps Fig05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph includes three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, comparing their effectiveness in pain improvement.*

FDA Label Image

Figure 6 (Pregabalincaps Fig06)

A bar chart comparing responder rates (%) for Pregabalin doses versus placebo in two studies, E1 and E3. The x-axis displays dose groups including placebo and various mg/day dosages, and the y-axis shows responder rate percentages from 0% to 60%. Study E1 presents data for placebo, 50, 150, 300, and 600 mg/day doses, showing increased responder rates with higher dosages. Study E3 compares placebo, 600 mg/day twice daily (BID), and 600 mg/day three times daily (TID), with higher responder rates at higher dosages.*

FDA Label Image

Figure 7 (Pregabalincaps Fig07)

A dose-response line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day) for Pregabalin in four different studies labeled E1 BID, E2 TID, E3 BID, and E3 TID. The graph shows increasing seizure reduction with higher doses, annotated with significant p-values at various points.*

FDA Label Image

Figure 8 (Pregabalincaps Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at various daily doses (300 mg, 450 mg, 600 mg) compared to placebo. The graph features four lines representing different dose levels and placebo, illustrating patient response distribution across pain improvement percentages.*

FDA Label Image

Figure 9 (Pregabalincaps Fig09)

A Kaplan-Meier survival curve comparing Pregabalin and placebo over 180 days. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis represents time in days. The solid line depicts Pregabalin, and the dashed line represents placebo, showing higher retention without LTR for Pregabalin throughout the study period.*

FDA Label Image

Figure 11 (Pregabalincaps Fig10)

A line graph comparing the percentage of subjects improved over time from baseline to Week 12 between Pregabalin and placebo groups. The x-axis shows the percentage improved, and the y-axis shows the percent of subjects improved. Two lines represent Pregabalin (solid) and placebo (dashed), indicating higher improvement percentages for Pregabalin.*

FDA Label Image

Figure 12 (Pregabalincaps Fig11)

A line graph depicting the percent of subjects improved from baseline to week 16 BOCF, comparing Pregabalin and Placebo. The x-axis shows percent improvement intervals from >0 to 100, and the y-axis represents the percent of subjects improved. Pregabalin has a higher percentage of subjects improved across the range compared to Placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalincaps Formula)

A formula panel displaying the creatinine clearance (CLcr) calculation equation used for dosing considerations, showing the relationship between age, weight, serum creatinine, and a female sex adjustment factor. This panel appears to be part of dosing guidance for Pregabalin capsules by Exelan Pharmaceuticals Inc.*

FDA Label Image

Chemical Structure (Pregabalincaps Str)

Chemical structure of Pregabalin showing its molecular configuration including a carboxylic acid group, an amine group, and several carbon chains as depicted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.